The Tolerability of Saracatinib in Subjects With Lymphangioleiomyomatosis (LAM) (SLAM-1)
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Lymphangioleiomyomatosis (LAM) is a rare lung disease that mostly affects women of
childbearing age. In LAM, abnormal, muscle-like cells begin to grow out of control in the
lungs. As a result, air can't move freely in and out of the lungs. In some cases, this means
the lungs can't supply the body's other organs with enough oxygen.
This study is being conducted to find out what dose of a drug called saracatinib is best
tolerated by people with LAM. This drug has been tested in patients with certain types of
cancer but is not currently approved by the United States Food and Drug Administration (FDA).
Saracatinib may work in cancer by preventing the growth, movement and invasiveness of cancer
cells. The use of saracatinib to treat LAM is considered experimental. Preliminary testing
already completed suggests that the study drug, saracatinib, may suppress certain substances
in the lungs of patients with LAM thus may be effective in slowing down the disease process